Research ExplorerPublicationsEvolution of liver stiffness and post-treatment surveillance...

Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era

Standard

Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era. / Piecha, Felix; Gänßler, Jan-Michael; Ozga, Ann-Kathrin; Wehmeyer, Malte H; Kluwe, Johannes; Lampalzer, Sibylle; Creutzfeldt, Anna Maria; Buescher, Gustav; Horvatits, Thomas; Sterneck, Martina; Pischke, Sven; Lohse, Ansgar W; Schulze Zur Wiesch, Julian.

In: SCAND J GASTROENTERO, Vol. 56, No. 7, 07.2021, p. 840-848.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Piecha, F, Gänßler, J-M, Ozga, A-K, Wehmeyer, MH, Kluwe, J, Lampalzer, S, Creutzfeldt, AM, Buescher, G, Horvatits, T, Sterneck, M, Pischke, S, Lohse, AW & Schulze Zur Wiesch, J 2021, 'Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era', SCAND J GASTROENTERO, vol. 56, no. 7, pp. 840-848. https://doi.org/10.1080/00365521.2021.1915374

APA

Piecha, F., Gänßler, J-M., Ozga, A-K., Wehmeyer, M. H., Kluwe, J., Lampalzer, S., Creutzfeldt, A. M., Buescher, G., Horvatits, T., Sterneck, M., Pischke, S., Lohse, A. W., & Schulze Zur Wiesch, J. (2021). Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era. SCAND J GASTROENTERO, 56(7), 840-848. https://doi.org/10.1080/00365521.2021.1915374

Vancouver

Piecha F, Gänßler J-M, Ozga A-K, Wehmeyer MH, Kluwe J, Lampalzer S et al. Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era. SCAND J GASTROENTERO. 2021 Jul;56(7):840-848. https://doi.org/10.1080/00365521.2021.1915374

Bibtex

@article{0215dc1d953e4707915f1821d1c9103d,
title = "Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era",
abstract = "OBJECTIVE: Baseline liver stiffness (LS) is prognostically relevant in patients with chronic hepatitis C virus (HCV) infection but may change after successful HCV eradication. Data on post-treatment LS for a further risk stratification remain scarce. Here, we study the kinetics of LS and laboratory parameters in patients undergoing HCV treatment and analyze the association of post-treatment LS with outcome parameters.METHODS: In a cohort of 1011 chronic HCV patients undergoing DAA treatment, we identified 404 patients with sequential LS and laboratory assessments with or without viral eradication. Additionally, outcome parameters were correlated with post-treatment LS after successful HCV therapy.RESULTS: LS significantly decreased from a median of 8.8 to 6.1 kPa in 346 patients after HCV eradication, but significantly increased from a median of 10.5 to 11.9 kPa in 58 patients without viral clearance. In 78 patients with two sequential post-treatment measurements, LS decreased from 12.6 to 8.7 kPa after a median 344 d, with a further decrease to 7.0 kPa after a median of 986 d after end of treatment (EoT). In 400 patients with a post-treatment LS assessment after viral eradication, only 9 liver-related events occurred over a median follow-up (FU) of 23 months. All events were observed in patients with a post-treatment LS >20 kPa.CONCLUSIONS: After successful HCV eradication, LS improves sequentially, suggesting an initial phase of necroinflammation regression followed by a second phase of true fibrosis regression. Overall, liver-related events were rarely observed and seem to be limited to patients with a post-treatment LS >20 kPa, so that these patients require a closer clinical monitoring.",
keywords = "Antiviral Agents/therapeutic use, Elasticity Imaging Techniques, Hepatitis C, Chronic/complications, Humans, Liver/diagnostic imaging, Liver Cirrhosis/diagnostic imaging",
author = "Felix Piecha and Jan-Michael G{\"a}n{\ss}ler and Ann-Kathrin Ozga and Wehmeyer, {Malte H} and Johannes Kluwe and Sibylle Lampalzer and Creutzfeldt, {Anna Maria} and Gustav Buescher and Thomas Horvatits and Martina Sterneck and Sven Pischke and Lohse, {Ansgar W} and {Schulze Zur Wiesch}, Julian",
year = "2021",
month = jul,
doi = "10.1080/00365521.2021.1915374",
language = "English",
volume = "56",
pages = "840--848",
journal = "SCAND J GASTROENTERO",
issn = "0036-5521",
publisher = "informa healthcare",
number = "7",

}

RIS

TY - JOUR

T1 - Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era

AU - Piecha, Felix

AU - Gänßler, Jan-Michael

AU - Ozga, Ann-Kathrin

AU - Wehmeyer, Malte H

AU - Kluwe, Johannes

AU - Lampalzer, Sibylle

AU - Creutzfeldt, Anna Maria

AU - Buescher, Gustav

AU - Horvatits, Thomas

AU - Sterneck, Martina

AU - Pischke, Sven

AU - Lohse, Ansgar W

AU - Schulze Zur Wiesch, Julian

PY - 2021/7

Y1 - 2021/7

N2 - OBJECTIVE: Baseline liver stiffness (LS) is prognostically relevant in patients with chronic hepatitis C virus (HCV) infection but may change after successful HCV eradication. Data on post-treatment LS for a further risk stratification remain scarce. Here, we study the kinetics of LS and laboratory parameters in patients undergoing HCV treatment and analyze the association of post-treatment LS with outcome parameters.METHODS: In a cohort of 1011 chronic HCV patients undergoing DAA treatment, we identified 404 patients with sequential LS and laboratory assessments with or without viral eradication. Additionally, outcome parameters were correlated with post-treatment LS after successful HCV therapy.RESULTS: LS significantly decreased from a median of 8.8 to 6.1 kPa in 346 patients after HCV eradication, but significantly increased from a median of 10.5 to 11.9 kPa in 58 patients without viral clearance. In 78 patients with two sequential post-treatment measurements, LS decreased from 12.6 to 8.7 kPa after a median 344 d, with a further decrease to 7.0 kPa after a median of 986 d after end of treatment (EoT). In 400 patients with a post-treatment LS assessment after viral eradication, only 9 liver-related events occurred over a median follow-up (FU) of 23 months. All events were observed in patients with a post-treatment LS >20 kPa.CONCLUSIONS: After successful HCV eradication, LS improves sequentially, suggesting an initial phase of necroinflammation regression followed by a second phase of true fibrosis regression. Overall, liver-related events were rarely observed and seem to be limited to patients with a post-treatment LS >20 kPa, so that these patients require a closer clinical monitoring.

AB - OBJECTIVE: Baseline liver stiffness (LS) is prognostically relevant in patients with chronic hepatitis C virus (HCV) infection but may change after successful HCV eradication. Data on post-treatment LS for a further risk stratification remain scarce. Here, we study the kinetics of LS and laboratory parameters in patients undergoing HCV treatment and analyze the association of post-treatment LS with outcome parameters.METHODS: In a cohort of 1011 chronic HCV patients undergoing DAA treatment, we identified 404 patients with sequential LS and laboratory assessments with or without viral eradication. Additionally, outcome parameters were correlated with post-treatment LS after successful HCV therapy.RESULTS: LS significantly decreased from a median of 8.8 to 6.1 kPa in 346 patients after HCV eradication, but significantly increased from a median of 10.5 to 11.9 kPa in 58 patients without viral clearance. In 78 patients with two sequential post-treatment measurements, LS decreased from 12.6 to 8.7 kPa after a median 344 d, with a further decrease to 7.0 kPa after a median of 986 d after end of treatment (EoT). In 400 patients with a post-treatment LS assessment after viral eradication, only 9 liver-related events occurred over a median follow-up (FU) of 23 months. All events were observed in patients with a post-treatment LS >20 kPa.CONCLUSIONS: After successful HCV eradication, LS improves sequentially, suggesting an initial phase of necroinflammation regression followed by a second phase of true fibrosis regression. Overall, liver-related events were rarely observed and seem to be limited to patients with a post-treatment LS >20 kPa, so that these patients require a closer clinical monitoring.

KW - Antiviral Agents/therapeutic use

KW - Elasticity Imaging Techniques

KW - Hepatitis C, Chronic/complications

KW - Humans

KW - Liver/diagnostic imaging

KW - Liver Cirrhosis/diagnostic imaging

U2 - 10.1080/00365521.2021.1915374

DO - 10.1080/00365521.2021.1915374

M3 - SCORING: Journal article

C2 - 34010581

VL - 56

SP - 840

EP - 848

JO - SCAND J GASTROENTERO

JF - SCAND J GASTROENTERO

SN - 0036-5521

IS - 7

ER -